Quantcast

BioTime CEO Dr. Michael West Presents Keynote Address at Event Commemorating the 10th Anniversary of the First Derivation of Human Embryonic Stem Cells

November 14, 2008

BioTime, Inc. (OTCBB:BTIM) Chief Executive Officer Michael West, Ph.D. will deliver a keynote presentation on Wednesday, November 19, at a meeting in Madison, Wisconsin commemorating the 10th anniversary of the publication describing the derivation and culturing of human embryonic stem cells for the first time. Dr. West’s presentation is titled “Opportunities and Challenges of Commercializing Stem Cell Research.”

The Wisconsin Academy, along with University of Wisconsin-Madison and the Wisconsin Alumni Research Foundation (WARF), will be hosting the two-day event titled “A Decade Celebrating Stem Cells: Changing the Face of Medicine Ten Years Later” to commemorate the 10th anniversary of the publication of the first derivation of human embryonic stem cells and to examine future trends. Other speakers for the event will include Wisconsin Governor Jim Doyle, Dr. James Thomson, former Governor of Wisconsin and U.S. Secretary of Health and Human Services Tommy Thompson, and WARF managing director Carl Gulbrandsen. Dr. West’s presentation will include a description of historical trends in the industry of commercializing stem cell technology, and a discussion of future opportunities for the field. Dr. West will discuss BioTime’s stem cell research that is focused on opportunities for near-term revenues in the development and marketing of products derived from stem cells, and Dr. West will also announce new developments in BioTime’s stem cell program.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions, and technology for use in surgery, emergency trauma treatment and other applications. BioTime’s lead product Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive licensing agreements.

BioTime has recently entered the field of regenerative medicine through its wholly owned subsidiary Embryome Sciences, Inc. where it plans to develop new medical and research products using embryonic stem cell technology. Additional information about BioTime can be found on the web at www.biotimeinc.com. Hextend(R), PentaLyte(R), HetaCool(R), Embryomics(TM), ESpy(TM), and ESpan(TM), are trademarks of BioTime, Inc.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,”"believes,”"plans,”"anticipates,”"expects,”"estimates,”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company’s business, particularly those mentioned in the cautionary statements found in the company’s Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://www.b2i.us/irpass.asp?BzID=1152&to=ea&s=0




comments powered by Disqus